Akari Therapeutics, Plc (AKTX) Stock: Price, Forecast & Analyst Target
Akari Therapeutics, Plc (AKTX) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $6.71 (-2.47%), as of the Nov 19, 2026 trading session; market cap $15.3M.
Educational signal · not a buy or sell recommendation · How to read this
Akari Therapeutics, Plc · AKTX · NASDAQ
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. Their lead product candidate, nomacopan, targets inflammatory and prothrombotic activities.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Akari Therapeutics (AKTX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a fragile balance sheet, stalling growth and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Fading; Momentum: Quiet.
Earnings yield is the main valuation drag relative to sector peers.
- EPS beat 2 of the last 8 reports
- Altman Z -13.46 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 30 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $6.71 | |
| Change on the day | -2.47% | |
| 52-week range | $3.02 – $29.32 | |
| Market capitalisation | $15.3M | — |
| Shares traded on the day | 9.8K |
Price & events
Other perspectives
Council score for Akari Therapeutics (AKTX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Akari Therapeutics (AKTX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Akari Therapeutics, Plc (AKTX) is listed on NASDAQ. It employs 6 people and is led by Abizer Gaslightwala. The market values it at $15.3M.
What do the latest results show for Akari Therapeutics (AKTX)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of the last 8 reports.
What are the financial strengths and risks for Akari Therapeutics (AKTX)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth. The distress and quality screens read Altman Z -13.46 · Piotroski F 2. Trailing ratios: ROA -80.4% · current ratio 0.48 · earnings yield -135.9% · free-cash-flow yield -86.0%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -13.46 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Akari Therapeutics (AKTX)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $9.58M · EPS -9.86 · 2 analysts. Current published price targets run low $19.50 · high $30.00 · consensus $24.75 · median $24.75 against a quoted price of $6.71 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for AKTX.
Checked against the records this page reads, on the dates shown above.
How does Akari Therapeutics compare with its peers?
Short answer
Akari Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Akari Therapeutics (AKTX) — this page | $6.71 | $15.3M | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $19.50 – $30.00
- Consensus target
- $24.75
- Median target
- $24.75
- Revenue estimate
- $9.58M
- EPS estimate
- $-9.86
Consensus record · Captured .
Measured against a quoted price of $6.71 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 14, 2026
- Transactions
- 48
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 0
- Other transactions
- 48
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AKTX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AKTX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Akari Therapeutics (AKTX)?
- Akari Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Progress
- Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
- Akari Therapeutics to Present RNA-Splicing ADC Payload Strategy at 3rd Annual ADC Payload Summit
- Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
Common Questions About AKTX
These answers are editorial: 1 of these 9 answers is drawn from the AKTX research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for AKTX?
AKTX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases.
Is AKTX a good stock to buy?
Stock Expert AI does not rate AKTX buy, sell or hold. Akari Therapeutics, Plc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the AKTX stock price today?
The last price recorded for Akari Therapeutics, Plc (AKTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AKTX price target?
The analyst consensus price target for Akari Therapeutics, Plc (AKTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for AKTX?
Akari Therapeutics, Plc faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as negative results could halt the development of nomacopan. The company's limited financial resources and reliance on external funding create financial risk.
What are the key factors to evaluate for AKTX?
Akari Therapeutics, Plc (AKTX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. With a small market cap, AKTX is highly sensitive to news flow and market sentiment. Not financial advice.
How frequently does AKTX data refresh on this page?
AKTX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven AKTX's recent stock price performance?
Akari Therapeutics, Plc (AKTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapeutic approach targeting the complement system. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AKTX overvalued or undervalued right now?
Akari Therapeutics, Plc (AKTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 21 figures on this page — 9 from Financial Modeling Prep (FMP), 10 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com